日本の再生医療市場2016-2020

◆英語タイトル:Regenerative Medicine Market in Japan 2016-2020
◆商品コード:IRTNTR10337
◆発行会社(調査会社):Technavio
◆発行日:2016年9月28日
◆ページ数:102
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:医療
◆販売価格オプション(消費税別)
Single User(1名利用)USD2,500 ⇒換算¥285,000見積依頼/購入/質問フォーム
Five User(~5名利用)USD3,000 ⇒換算¥342,000見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD4,000 ⇒換算¥456,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(支払期限と方法は調整可能、振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※レポート購入後、該当レポートに記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTechnavio社の日本における正規販売代理店です。Technavio社の概要及び新刊レポートはこちらでご確認いただけます。



当調査レポートでは、日本の再生医療市場について調査・分析し、エグゼクティブサマリー、市場概観、市場概観、業界の構造分析、日本の再生医療市場規模及び予測、用途別分析、製品別分析、市場の成長要因、市場の課題、医療費償還シナリオ、製品パイプライン分析、市場動向、競争状況、主要企業(ベンダー)分析などの情報をお届けいたします。
【レポートの概要】

About Regenerative Medicine
Regenerative medicine deals with the process of using therapeutically induced or laboratory-grown human tissue to treat damaged or diseased human cells, tissues, or organs. It focuses on repairing, replacing, or regenerating damaged cells, and thus offers a paradigm shift in healthcare treatment. The three main technologies used in regenerative medicine are small molecules and biologics, gene therapy, and cell therapy. Small molecules and biologics help in the regeneration of diseased cells and tissues, whereas cell therapy helps in treating the functioning of existing cells.

Technavio’s analysts forecast the regenerative medicine market in Japan to grow at a CAGR of 35.3% during the period 2016-2020.

[Covered in this report]
The report covers the present scenario and the growth prospects of the regenerative medicine market in Japan for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of various types of regenerative medicine products to end-users like hospitals, ambulatory surgical centers (ASCs), and clinical research laboratories.

The market is divided into the following segments based on product:
• Tissue Scaffold
• Cell Therapy

Technavio’s report, Regenerative Medicine Market in Japan 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

[Key vendors]
• CellSeed
• JCR Pharmaceuticals
• Japan Tissue Engineering
• Terumo
• Astellas
• Caladrius Biosciences
• Healios
• Fujifilm
• Rohto Pharmaceuticals

[Other prominent vendors]
• FUJISOFT Tissue Engineering
• MediBIC
• MEDI NET
• Nikon
• TAKARA
• CMIC
• EPS
• Cyfuse Biomedical
• Irvine Scientific
• Kaken
• Regience
• Sumitomo Dainippon
• Takeda
• Alfresa
• MEDIPAL Holdings
• TOHO

[Market driver]
• Growing partnerships of MNCs with local vendors in Japan
• For a full, detailed list, view our report

[Market challenge]
• High cost and failure rate in clinical trials coupled with inadequate clinical evidence
• For a full, detailed list, view our report

[Market trend]
• Strong pipeline portfolio of regenerative medicines
• For a full, detailed list, view our report

[Key questions answered in this report]
• What will the market size be in 2020 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

※You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.

【レポートの目次】

PART 01: Executive summary
• Highlights

PART 02: Scope of the report
• Market overview
• Top-vendor offerings

PART 03: Market research methodology
• Research methodology
• Economic indicators

PART 04: Introduction
• Key market highlights

PART 05: Healthcare reforms in Japan

PART 06: Regulatory landscape in Japan
• ASRM
• PMD Act

PART 07: Reimbursement scenario
• Reimbursement scenario for regenerative medicine in Japan

PART 08: Gene therapy: An emerging field in regenerative medicine

PART 09: Pipeline portfolio

PART 10: Market landscape
• Market overview
• Five forces analysis

PART 11: Market segmentation by product
• Cell therapy
• Cell therapy regenerative medicine market in Japan
• Tissue scaffold
• Tissue scaffold regenerative medicine market in Japan

PART 12: Market segmentation by application
• Dermatology
• Musculoskeletal
• Cardiovascular
• Other

PART 13: Market drivers
• Transformation of regulatory landscape fostering quick approval of regenerative medicines
• Growing partnerships of MNCs with local vendors in Japan
• Recent product approvals fuel the market growth
• Government initiatives driving regenerative medicine market in Japan

PART 14: Impact of drivers

PART 15: Market challenges
• Ethical challenges involved in regenerative medicine
• High cost and failure rate in clinical trials coupled with inadequate clinical evidence
• Low competitive edge of Japanese regenerative medicine market over other developed nations

PART 16: Impact of drivers and challenges

PART 17: Market trends
• Strong pipeline portfolio of regenerative medicines
• Entry of new players expanding the applications of regenerative medicine
• Strategic collaborations and acquisitions
• Advent of 3D tissue bioprinters for the development of regenerative medicines

PART 18: Vendor landscape
• Competitive scenario
• Key news
• Product approvals
• Partnerships
• Mergers and acquisitions
• Other

PART 19: Key vendor analysis
• CellSeed
• JCR Pharmaceuticals
• Japan Tissue Engineering (J-TEC)
• Terumo
• Upcoming vendors
• Other prominent vendors

PART 20: Appendix
• List of abbreviations

PART 21: Explore Technavio

[List of Exhibits]

Exhibit 01: Product offerings
Exhibit 02: Regenerative medicine application in various therapeutics
Exhibit 03: Major applications of regenerative medicine in Japan
Exhibit 04: Regenerative medicine legislation acts in Japan
Exhibit 05: Product approval and regulatory characteristics in Japan
Exhibit 06: Overview of regenerative medicine regulation acts
Exhibit 07: Landscape of regenerative medicine in Japan
Exhibit 08: Risk categories of regenerative medical technologies
Exhibit 09: Regenerative medicine approval process in Japan under the ASRM
Exhibit 10: Regenerative medicine approval process in Japan under PMD Act
Exhibit 11: Comparison of traditional and new product approval process under the PMD Act
Exhibit 12: Conditional approvals for regenerative medical products versus regular approval for pharmaceuticals
Exhibit 13: Japan’s NHI pricing methods
Exhibit 14: NHI pricing calculation for TEMCELL HS
Exhibit 15: NHI pricing calculation for HeartSheet A kit
Exhibit 16: NHI pricing calculation for HeartSheet B kit
Exhibit 17: Gene therapy research by sponsorship
Exhibit 18: Regenerative medicine pipeline products in Japan
Exhibit 19: Pipeline analysis of regenerative medicine in Japan 2015
Exhibit 20: Pipeline products of regenerative medicine for cell therapy in 2015
Exhibit 21: Key developments in regenerative medicine market in Japan 2015
Exhibit 22: Regenerative medicine market in Japan 2015-2020 ($ millions)
Exhibit 23: Regenerative medicine market in Japan: Optimistic and pessimistic analyses 2015-2020
Exhibit 24: Optimistic and pessimistic market analysis of regenerative medicine in Japan 2015-2020
Exhibit 25: Five forces analysis
Exhibit 26: Regenerative medicine market in Japan by product 2015 and 2020
Exhibit 27: Positioning of segments (by product type) in regenerative medicine market in Japan 2015
Exhibit 28: Regenerative medicine market in Japan: Lifecycle analysis by product 2015
Exhibit 29: Cell therapy overview
Exhibit 30: Ethical issues involved in different cell therapy research category
Exhibit 31: Stem cell research policies in Japan
Exhibit 32: Key cell therapy products marketed in Japan
Exhibit 33: Cell therapy regenerative medicine market in Japan 2015-2020 ($ millions)
Exhibit 34: Opportunity analysis of cell therapy regenerative medicine market in Japan
Exhibit 35: Collaborations for R&D of tissue scaffold
Exhibit 36: Tissue scaffold regenerative medicine market in Japan 2015-2020 ($ millions)
Exhibit 37: Opportunity analysis of tissue scaffold in Japan regenerative medicine market
Exhibit 38: Regenerative medicine market in Japan by product type 2015-2020 ($ millions)
Exhibit 39: Regenerative medicine market in Japan 2015-2020 (%)
Exhibit 40: Overview of the regenerative medicine dermatology market in Japan
Exhibit 41: Pipeline of regenerative medicine for dermatology
Exhibit 42: Overview of musculoskeletal regenerative medicine market in Japan
Exhibit 43: Overview of cardiovascular regenerative medicine market in Japan
Exhibit 44: Regulatory guidelines in Japan
Exhibit 45: Approval process of SAKIGAKE assignment system
Exhibit 46: Partnerships of MNCs with local vendors in Japan
Exhibit 47: MHLW budget on drug discovery using iPS cells ($ millions)
Exhibit 48: Impact of drivers
Exhibit 49: Force field analysis of regenerative medicine market in Japan
Exhibit 50: Impact of drivers and challenges
Exhibit 51: Regenerative medicine pipeline portfolio 2015
Exhibit 52: Current applications of regenerative medicine
Exhibit 53: Future applications of regenerative medicine
Exhibit 54: Major strategic collaborations and acquisitions in Japan
Exhibit 55: Impact of trends in regenerative medicine in Japan 2015-2020
Exhibit 56: Presence of vendors in regenerative medicine
Exhibit 57: CellSeed: Profile
Exhibit 58: CellSeed: Strength analysis
Exhibit 59: CellSeed: Growth strategy matrix
Exhibit 60: CellSeed: Opportunity assessment
Exhibit 61: JCR Pharmaceuticals: Profile
Exhibit 62: JCR Pharmaceuticals: Strength analysis
Exhibit 63: JCR Pharmaceuticals: Growth strategy matrix
Exhibit 64: JCR Pharmaceuticals: Opportunity assessment
Exhibit 65: J-TEC: Profile
Exhibit 66: J-TEC: Strength analysis
Exhibit 67: J-TEC: Growth strategy matrix
Exhibit 68: J-TEC: Opportunity assessment
Exhibit 69: Terumo: Profile
Exhibit 70: Terumo: Strength analysis
Exhibit 71: Terumo: Growth strategy matrix
Exhibit 72: Terumo: Opportunity assessment



【掲載企業】

CellSeed, JCR Pharmaceuticals, Japan Tissue Engineering, Terumo, Astellas, Caladrius Biosciences, Healios, Fujifilm,Rohto Pharmaceuticals, FUJISOFT Tissue Engineering, MediBIC, MEDI NET, Nikon, TAKARA, CMIC, EPS, Cyfuse Biomedical, Irvine Scientific, Kaken, Regience, Sumitomo Dainippon, Takeda, Alfresa, MEDIPAL Holdings, and TOHO.

【レポートのキーワード】

再生医療、日本

【調査方法】

一次資料による調査(業界専門家、ベンダー、代理店、顧客等を対象にしたデプスインタビュー調査など)及び二次資料による調査(Technavio独自のプラットフォーム、産業書籍、企業報告書、ニュース記事、アナリストレポート、貿易協会、政府機関発行データなど)

【免責事項】
※当レポート上の情報/データは調査会社が信頼できると判断した情報源から入手したものに基づき作成しましたが、その正確性・完全性を保証するものではありません。当レポートに記載された情報/データ/見解/仮説などは作成時点又は発行時点における調査会社の判断であり、その後の状況変化に応じて変更される場合があります。当レポート上の情報/データに基づいたお客様の意思決定又は実行による結果について、調査会社/発行会社/販売会社H&Iグローバルリサーチ(株)はその責を負いかねますのでご了承ください。英文資料の紹介ページにおける日本語題名/概要/目次はH&Iグローバルリサーチ(株)が翻訳した内容であり、翻訳の正確性・完全性を保証するものではありません。

★調査レポート[日本の再生医療市場2016-2020]についてメールでお問い合わせはこちら


※世界の市場調査資料 総合販売サイトMarketReport.jpはH&Iグローバルリサーチ株式会社が運営しております。海外進出、グローバル事業戦略策定、新規事業機会の発掘、競合他社の動向把握などに必要な情報やインサイトをお客様にご提供しております。H&Iグローバルリサーチ(登録第5864124号)及びH&I(登録第5783645号)はH&Iグローバルリサーチ株式会社の商標です。
※当サイトでは2016年12月09日現在 219,203 件の調査レポートを取り扱っております。当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。

◆H&Iグローバルリサーチのお客様(例)◆